S-1: Reliance Global Group Files for Resale of 4.2 Million Shares Issuable Upon Exercise of Series G Warrants

Reliance Global Group is registering for resale up to 4,210,528 shares of its common stock issuable upon the exercise of Series G warrants held by a selling securityholder.

Summary

• Reliance Global Group, Inc. has filed a registration statement for the resale of up to 4,210,528 shares of its common stock.
• These shares are issuable upon the exercise of Series G warrants held by Armistice Capital Master Fund Ltd.
• The Series G warrants were issued in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
• Each Series G warrant entitles the holder to purchase one share of common stock at an exercise price of $0.6562 per share.
• The company will not receive any proceeds from the sale of shares by the selling securityholder, but will receive proceeds from the exercise of the Series G warrants if exercised for cash.
• The company intends to use any net proceeds from the cash exercise of these warrants for working capital, debt payments, and general corporate purposes.
• The selling securityholder may sell the shares at fixed prices, market prices, related to market prices, or negotiated prices.
• The last reported sale price per share of Reliance Global Group's common stock on the Nasdaq Capital Market on January 12, 2024, was $0.4875.
• The Series G Warrants are not exercisable until the Company obtains the approval of a sufficient amount of holders of its common stock to satisfy the shareholder approval requirements for such action as provided in Nasdaq Rule 5635(e).

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on the registration of shares for resale. While the potential warrant exercise could provide capital, the current stock price being below the exercise price and the need for shareholder approval introduce uncertainty.

Positives

• The company could receive up to approximately $2,762,948 in gross proceeds if all Series G Warrants are exercised for cash.
• The company intends to use the proceeds for working capital, debt payments, and general corporate purposes, which could support growth.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling securityholder unless the warrants are exercised for cash.
• The market price of the common stock on January 12, 2024, was $0.4875, which is below the exercise price of the Series G warrants ($0.6562).
• The Series G Warrants are not exercisable until the Company obtains the approval of a sufficient amount of holders of its common stock to satisfy the shareholder approval requirements for such action as provided in Nasdaq Rule 5635(e).

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company's business is influenced by many factors that are difficult to predict and that involve uncertainties that may materially affect operating results, cash flows, and financial condition.
• The selling securityholder may sell all, some, or none of their shares in this offering, creating uncertainty about the potential dilution and market impact.
• The Series G Warrants are not exercisable until the Company obtains the approval of a sufficient amount of holders of its common stock to satisfy the shareholder approval requirements for such action as provided in Nasdaq Rule 5635(e).

Future Outlook

The company plans to expand and grow its footprint and market share both through organic growth, and by expansion through additional acquisitions in various insurance markets over the next 12 months. The company expects to close on multiple M&A transactions over the course of the next three years.

Industry Context

The company operates in the insurance markets and related sectors, focusing on acquisitions and development of specialized programs. It competes with other insurance agencies, technology companies, and financial services firms.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To assess RELI's performance against industry benchmarks, one would need to compare its growth rate, profitability, and efficiency metrics (e.g., revenue per employee, customer acquisition cost) against those of comparable companies like Brown & Brown, Acrisure, Gallagher, or Hub International.
• Additionally, comparing RELI's InsurTech platform (5MinuteInsure.com and RELI Exchange) to other platforms like SelectQuote or Policygenius would provide insights into its competitive positioning and technological advantages.

Related Party Transactions

• In September 2018, Reliance Global Holdings, LLC, a related party, purchased a controlling interest in the company.

Stakeholder Impact

• Shareholders may experience dilution if the Series G warrants are exercised.
• The company's ability to execute its growth strategy could be affected by the availability of working capital, which may depend on the exercise of the warrants.

Next Steps

• The company needs to obtain shareholder approval to allow the exercise of the Series G Warrants.
• The selling securityholder may offer and sell the shares of common stock from time to time.
• The company will use commercially reasonable efforts to cause the Resale Registration Statement to become effective within 90 calendar days following the Closing Date and agreed to use commercially reasonable efforts to keep the Resale Registration Statement effective at all times.

Key Dates

Keywords

Series G Warrants, common stock, resale, registration statement, Reliance Global Group, Armistice Capital, exercise price, securities, offering, warrants